News | June 04, 2024
Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The state-of-the-art facility is equipped with best-in-class equipment and control systems
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Executes the first project for developing and manufacturing a novel anticancer mAb
To accelerate the development of next-generation radioconjugates to treat cancer
Sen spent a decade with Biocon and held various key roles,
Subscribe To Our Newsletter & Stay Updated
